- - oalib

OALib Journal期刊
ISSN: 2333-9721
费用：99美元

投递稿件

为什么选择我们？ >>

- 开源期刊

- 同行审议

- 快速出刊

- 终身存储

- 免费检索

- 免费推广

- 更多...

- 搜索引擎

-

ISSN Print: 1532-1827

ISSN Online:

主页: https://www.nature.com/bjc

分享:

Physical activity during adolescence and risk of colorectal adenoma later in life: results from the Nurses’ Health Study II

Ingested asbestos in filtered beer, in addition to occupational exposure, as a causative factor in oesophageal adenocarcinoma

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes

A NOTCH added to metabolomics

Moving from one to many: insights from the growing list of pleiotropic cancer risk genes

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment

Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

How rapid advances in imaging are defining the future of precision radiation oncology

Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer

Predictive value of inflammatory markers for cancer diagnosis in primary care: a prospective cohort study using electronic health records

Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany

A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution

A systematic review and quality assessment of individualised breast cancer risk prediction models

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma

Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features

Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer

A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer

Coffee consumption by type and risk of digestive cancer: a large prospective cohort study

Lipid metabolism in cancer cells under metabolic stress

Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

Poor outcome in hypoxic endometrial carcinoma is related to vascular density

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)

CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer

Cell lines and immune classification of glioblastoma define patient’s prognosis

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation

A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide

Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts

Understanding the impact of socioeconomic differences in colorectal cancer survival: potential gain in life-years

Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

Prediabetes and diabetes in relation to risk of gastric adenocarcinoma

Case–control study of paternal occupational exposures and childhood lymphoma in Great Britain, 1962–2010

LGR5 expression predicts peritoneal recurrence after curative resection of primary colon cancer

ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma

Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations

Family history of cancer and risk of paediatric and young adult’s testicular cancer: A Norwegian cohort study

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

Oncofoetal insulin receptor isoform A marks the tumour endothelium; an underestimated pathway during tumour angiogenesis and angiostatic treatment

Long-term risk of screen-detected and interval breast cancer after false-positive results at mammography screening: joint analysis of three national cohorts

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer

Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts

©2008-2017 OALib, Inc | Public user content licensed CC-BY 4.0 unless otherwise specified. OALib ISSN Online: 2333-9721 OALib ISSN Print: 2333-9705